Research in contextEvidence before this studySpontaneous intracerebral hemorrhage is a devastating disease with high mortality rate, and it accounts for 10--15% of all cases of stroke. Previous research shows that hematoma volume is a powerful and easy-to-use determinant of 30-day mortality, and hematoma expansion is associated with poor outcomes. Reducing hematoma growth and mortality is the current focus of clinical trials. Therefore, successfully predicting hematoma expansion is necessary and valuable for therapeutic intervention in patients with ICH. Many clinical variables have been used for the prediction of hematoma expansion; however, the prediction performance is generally not good.Added value of this studyBy combining different variables, including patients\' demographic parameters, clinical status, laboratory test parameters, and image signs, we developed a prediction model by using support vector machine method. Our model demonstrated a good performance in prediction of hematoma expansion.Implications of all the available evidenceSupport vector machine may provide a valuable tool in prediction of hematoma expansion for patients with spontaneous intracerebral hemorrhage. Our prediction model may be practical and widely applicable, especially in many institutions where CTA is not readily available or routinely performed for spontaneous intracerebral hemorrhage patients.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Spontaneous intracerebral hemorrhage (ICH) refers to bleeding within the brain parenchyma that may extend into the ventricles or subarachnoid space \[[@bb0005]\]. As a devastating disease with high mortality rate, it accounts for 10--15% of all cases of stroke \[[@bb0005]\]. Although modern medical science and technology have been developing fast, a safe and effective therapeutic method for ICH is elusive, and the overall mortality of ICH remains high. Hematoma volume is a powerful and easy-to-use determinant of 30-day mortality \[[@bb0010]\], and hematoma expansion is associated with poor outcomes \[[@bb0015], [@bb0020], [@bb0025]\]. Reducing hematoma growth and mortality is the current focus of clinical trials, such as INTERACT \[[@bb0030]\], ATACH-II \[[@bb0035]\], STOP-AUST \[[@bb0040]\], FAST \[[@bb0045]\], STOP-IT \[[@bb0050]\], and SPOTLIGHT \[[@bb0050]\]. Because hematoma expansion is a treatment target of clinical interventions in patients with ICH, it is meaningful to predict hematoma expansion.

Various factors of hematoma expansion have been determined in recent decades, including initial hematoma volumes \[[@bb0010]\], anticoagulation use \[[@bb0055]\], alcohol consumption \[[@bb0060]\], time interval between onset and admission \[[@bb0065]\], computed tomography (CT) imaging findings such as black hole sign \[[@bb0025]\] and spot sign \[[@bb0040]\], and laboratory parameters such as platelet counts and fibrinogen levels \[[@bb0060]\]. However, accurately predicting hematoma expansion remains challenging because of the complex association between these risk factors and hematoma expansion \[[@bb0070]\]. Machine learning technique may be used to solve this problem. As a promising supervised machine learning technique, support vector machine (SVM) is capable of learning from the observing data sets, devising complex models to capture the intrinsic relationships between input and output variables, and making data-driven predictions or decisions, and it has been successfully applied in multiple biomedicine fields and demonstrated great performance \[[@bb0075],[@bb0080]\].

In this study, we aimed to predict hematoma expansion in spontaneous ICH from routinely available variables using SVM method.

2. Materials and methods {#s0025}
========================

2.1. Patients and clinic variables {#s0030}
----------------------------------

This study was approved by our institutional ethics committee, and written informed consent was waived. We retrospectively reviewed patients aged \>18 years who had spontaneous ICH in our hospital between September 2013 and August 2018. A total of 8722 patients were identified from the radiological information system by use of the search key words "hemorrhage" and "hematoma", and they were eligible for the study if the initial and follow-up CT scans were performed within 6 and 72 h after symptom onset, respectively. Patients were excluded from the study if they had hemorrhage due to cerebral aneurysm, arteriovenous malformation, brain tumor, traumatic brain injury, or hemorrhagic infarction. Those receiving anticoagulation or antiplatelet therapy or those underwent surgical intervention before the follow-up CT scan were also excluded from the study. Finally, a total of 1157 patients were enrolled in this study. For the purpose of model validation, additional independent dataset for testing was collected from a different affiliated hospital of our university between March 2017 and August 2018. After exclusion from 1960 patients, 105 patients were included as the additional test dataset.

After admission, patients\' age, sex, and neurological findings were recorded. Parameters of laboratory blood test, including glucose, white blood cell count, platelet count, hemoglobin, red blood cell, albumin, alanine transaminase, aspartate transaminase, total cholesterol, triglyceride, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides, international normalized ratio, and fibrinogen etc., were collected. In addition, Glasgow Coma Score, history of hemorrhage, history of hypertension, history of infarction, history of diabetes mellitus, and smoking and drinking habits were documented.

2.2. Image acquisition {#s0035}
----------------------

Noncontrast CT scan images were acquired by using a 64-channel multidetector CT scanner (LightSpeed VCT 64; GE Medical Systems, Milwaukee, WI, USA) with a slice thickness of 5 mm and a reconstruction interval of 5 mm, or a 16-channel multidetector CT scanner (BrightSpeed; GE Medical Systems, Milwaukee, WI, USA) with a slice thickness of 5 mm and a reconstruction interval of 5 mm. Patient orientation was head first. Reconstruction algorithm was 'Stnd'. The image matrix size was 512 × 512.

2.3. Radiological characterization and definition of hematoma expansion {#s0040}
-----------------------------------------------------------------------

Hematoma region in each slice was manually segmented, and corresponding hematoma volume was measured on initial and follow-up CT scans using GE Healthcare Advantage Workstation 4.6. Hematoma expansion was defined as a proportional increase of hematoma volume \> 33% or an absolute growth of hematoma volume \> 6 mL from initial CT scan to follow-up CT scan \[[@bb0070],[@bb0085],[@bb0090]\].

Radiological characteristics were independently evaluated by two experienced radiologists who were blinded to the clinical information of patients. Midline shift \[[@bb0095]\] in the CT slice with the maximum hematoma area was measured on GE Healthcare Advantage Workstation 4.6. CT image findings, including intraventricular extension \[[@bb0100]\], black hole sign \[[@bb0025]\], blend sign \[[@bb0105]\], and satellite sign \[[@bb0110]\] were assessed on initial CT scan. [Fig. 1](#f0005){ref-type="fig"} shows typical examples of black hole sign, blend sign, and satellite sign.Fig. 1Illustration of CT image findings: (a) Black hole sign; (b) Blend sign; (c) Satellite sign.Fig. 1

2.4. Support vector machine {#s0045}
---------------------------

In recent years, SVM has been introduced to solve various biomedicine problems \[[@bb0115],[@bb0120]\]. As a supervised machine learning method, SVM aims to classify data points by maximizing the margin between classes. It can be used for non-linear classification using kernel trick \[[@bb0115]\], implicitly mapping the inputs into high-dimension feature spaces using different kernel function. In this study, the radial basis function (RBF) kernel function was adopted. Of the included 1157 patients, 925 random patients (80%) were selected for training and the remaining 232 patients (20%) for testing. The recursive feature elimination method was applied for feature selection using the training dataset. The input features can be recorded in the formats of 'xlsx' or 'cvs' and uploaded into the SVM model. Randomized search strategy was implemented for tuning parameters of our classifier, and a 10-fold cross-validation approach was used during the training. Parameters C and γ were determined to be 9.222 and 0.009, respectively. An interpreted, high-level, and open-source programming language Python 2.7 and an efficient data mining tool Scikit-learn 0.20.1 were used for machine learning coding \[[@bb0125]\].

The performance of SVM was evaluated by sensitivity, specificity, overall accuracy, and area under the receiver operating characteristic curve (AUC). Overall accuracy is the ratio of correctly predicted patients.

2.5. Statistical analysis {#s0050}
-------------------------

Statistical analysis was performed using the software package IBM SPSS 22.0 (IBM SPSS, Armonk, New York, USA). Continuous variables were presented as means ± standard deviations and categorical variables as frequency (percentage). Student *t-*tests or Mann-Whitney *U* tests were applied for comparison of continuous variables, and *χ*^2^ tests or Fisher exact tests were used for comparison of categorical variables, as appropriate. It was of great significance to understand the relationship between independent variables and the dependent variable in clinics. The multivariate logistic analysis could be used to determine the independent risk factors and obtain odds ratio in the presence of more than one explanatory variable \[[@bb0130]\]. Multivariate logistic regression model with a forward method was performed to identify factors that were independently associated with hematoma expansion. Baseline variables clinically relevant with outcome with a *P*-value \< .05 on univariate analysis were considered in the multivariate logistic regression analysis. Variables with \>5% missing values were not involved in the multivariate logistic regression analysis. Given the number of events available, the variables for inclusion were determined to ensure parsimony of the final logistic regression model. Note that feature selection was applied to select a subset of relevant feature for use in the machine learning model for shorting training time, avoiding the curse of dimensionality, and simplifying models \[[@bb0135]\]. The selected features were not necessary to be exactly the same as the independent risk factors from multivariate analysis.

3. Results {#s0055}
==========

Of the included 1157 patients with ICH, 246 (21.3%) experienced hematoma expansion. The mean age was 61.6 ± 12.8 years (range 19--95) and 760 patients (65.7%) were male. The incidence of hematoma expansion in female was lower than that in male patients (59 of 397 \[14.9%\] vs 187 of 760 \[24.6%\]). Of the validation patients, there were 67 men and 38 women; their mean age was 60.4 ± 14.0 years; 19 patients had hematoma expansion.

A comparison of variables between expanders and nonexpanders is provided in [Table 1](#t0005){ref-type="table"}. Hematoma expansion occurred more commonly in male patients (*P* \< .001), and it was associated with shorter time from symptom onset to initial CT scan (2.6 ± 1.3 vs. 3.2 ± 1.4 h, *P* \< .001) and larger mean hematoma volume on the initial CT scan (26.83 ± 18.64 vs. 19.84 ± 15.03 mL, *P* \< .001). Laboratory examine parameters, including platelet, hemoglobin, red blood cell count, albumin, fibrinogen, total cholesterol, and LDL-C were statistically different between expanders and nonexpanders. CT imaging findings, including black hole sign, blend sign, and satellite sign, were more commonly found in expanders than in nonexpanders (all *P* \< .001). Midline shift was larger in patients with hematoma expansion than those without (*P* \< .001). The multivariate logistic regression analysis ([Table 2](#t0010){ref-type="table"}) revealed that male patient, time to initial CT, Glasgow Coma Scale, fibrinogen level, black hole sign, and blend sign were independently associated with hematoma expansion.Table 1Comparison of variables between expanders and nonexpanders.Table 1Clinical variablesExpander (246)Nonexpander (911)*P* ValueMen187 (76.0%)573 (62.9%)\<.001Age (years)61.0 ± 12.961.7 ± 12.8.408Glasgow Coma Score [a](#tf0005){ref-type="table-fn"}10.9 ± 3.512.4 ± 3.1\<.001Time to initial CT scan (h)2.6 ± 1.33.2 ± 1.4\<.001Reexamine time (h)16.0 ± 14.423.5 ± 15.9\<.001Platelet (×10^9^/L) [b](#tf0010){ref-type="table-fn"}197 ± 64209 ± 76.026Hemoglobin (g/L) [b](#tf0010){ref-type="table-fn"}142 ± 19138 ± 16.001White blood cell (×10^9^/L) [b](#tf0010){ref-type="table-fn"}9.49 ± 4.019.94 ± 3.70.066Red blood cell (×10^12^/L) [b](#tf0010){ref-type="table-fn"}4.61 ± 0.574.50 ± 0.56.005Glucose (mmol/L) [b](#tf0010){ref-type="table-fn"}7.74 ± 2.657.77 ± 2.68.860International normalized ratio [c](#tf0015){ref-type="table-fn"}1.05 ± 0.271.01 ± 0.15.014Fibrinogen (g/L) [c](#tf0015){ref-type="table-fn"}3.15 ± 0.813.50 ± 1.03\<.001Albumin (g/L) [d](#tf0020){ref-type="table-fn"}39.1 ± 5.340.0 ± 5.5.043Alanine transaminase (U/L) [e](#tf0025){ref-type="table-fn"}31 ± 2029 ± 32.365Aspartate transaminase (U/L) [f](#tf0030){ref-type="table-fn"}33 ± 1930 ± 22.130Total cholesterol (mmol/L) [g](#tf0035){ref-type="table-fn"}4.95 ± 1.485.29 ± 1.28.002Triglycerides (mmol/L) [g](#tf0035){ref-type="table-fn"}1.57 ± 1.341.67 ± 1.44.346HDL-C (mmol/L) [g](#tf0035){ref-type="table-fn"}1.26 ± 0.351.29 ± 0.59.476LDL-C (mmol/L) [g](#tf0035){ref-type="table-fn"}2.90 ± 1.143.17 ± 0.99.001Baseline hematoma volume (mL)26.83 ± 18.6419.84 ± 15.03\<.001Location of hemorrhage.279Deep gray matter205 (83.3%)745 (81.8%)Lobar regions20 (8.1%)78 (8.6%)Cerebellum5 (2.0%)44 (4.8%)Brain stem6 (2.4%)20 (2.2%)Multiple locations10 (4.1%)24 (2.6%)Intraventricular extension101 (41.1%)328 (36.0%).145Black hole sign68 (27.6%)111 (12.2%)\<.001Blend sign88 (35.8%)115 (12.6%)\<.001Satellite sign147 (59.8%)429 (47.1%)\<.001Midline shift (mm) [h](#tf0040){ref-type="table-fn"}4.17 ± 2.953.38 ± 2.57\<.001History of hemorrhage15 (6.1%)31 (3.4%).055History of infarction8 (3.3%)42 (4.5%).353History of diabetes mellitus23 (9.3%)100 (11.0%).586History of hypertension176 (71.5%)728 (79.9%).005Smoking71 (28.9%)253 (27.8).735Drinking76 (30.9%)248 (27.2%).255[^1][^2][^3][^4][^5][^6][^7][^8][^9]Table 2Results of multivariate logistic regression analysis.Table 2Variableβ coefficient[†](#tf0045){ref-type="table-fn"}OR95% CI*P*-valueMen0.60 ± 0.191.821.26--2.63.001Time to initial CT scan−0.32 ± 0.060.730.65--0.83\<.001Glasgow Coma Score−0.15 ± 0.030.860.82--0.90\<.001Fibrinogen level−0.33 ± 0.100.720.59--0.87.001Black Hole sign0.93 ± 0.212.521.69--3.78\<.001Blend sign1.39 ± 0.194.032.77--5.85\<.001[^10][^11]

Nine features were selected as the input of SVM model, including fibrinogen level, sex, Glasgow Coma Score, time to initial CT scan, black hole sign, blend sign, satellite sign, midline shift, and baseline hematoma volume. [Table 3](#t0015){ref-type="table"} demonstrates the prediction results for the two independent test datasets using the developed SVM model. For the first independent test dataset, the sensitivity was 83.7%, the specificity was 85.8%, and the overall accuracy was 85.3%, respectively. For the additional independent test dataset, the sensitivity was 78.9%, the specificity was 83.7%, and the overall accuracy was 81.3%. [Fig. 2](#f0010){ref-type="fig"} illustrates the ROC curves for the two independent test datasets. The AUC values for the internal and external test datasets were 0.93 and 0.85, respectively. Thus, the mean values of sensitivity, specificity, overall accuracy, AUC for the two test datasets were 81.3%, 84.8%, 83.3%, and 0.89, respectively.Table 3Prediction results for two independent test datasets.Table 3Actual classPredicted classExpanderNonexpander% correct(a) Test dataset 1Expander41883.7%Nonexpander2615785.8%Overall85.3%  (b)Test dataset 2Expander15478.9%Nonexpander147283.7%Overall81.3%Fig. 2Receive operating characteristic curves for two independent test datasets.Fig. 2

4. Discussion {#s0060}
=============

In the present study, the association between many clinical variables and hematoma expansion were assessed and the independent predictors were determined by multivariate logistic regression analysis from 1157 patients with spontaneous ICH. A SVM model was developed and applied to predict hematoma expansion, and a good performance was achieved.

The incidence of hematoma expansion varies from 13% to 34% across different studies \[[@bb0015],[@bb0070],[@bb0140]\], most likely because of different definitions of hematoma expansion, time to initial CT scan, and hematoma volume measurement. In our study hematoma expansion occurred in 21.3% patients with ICH. Using same definition of hematoma expansion and time to initial CT scan as ours, 33.7% patients with ICH had hematoma expansion in the study of Li et al. \[[@bb0140]\]. Accuracy of hematoma volume measurement is also crucial for hematoma expansion analysis. Methods of ABC/2 and modified ABC/2 have been developed for hematoma volume measurement \[[@bb0010],[@bb0025],[@bb0145]\]; however, these techniques should be used with caution, especially in calculation of irregular and discontinuous hematomas \[[@bb0150]\]. Hematoma region in our study was manually drawn slice by slice, and corresponding volume was calculated after 3-dimensional reconstruction. Although our volume measurement is relatively time-consuming, hematoma volume measurement may be more accurate.

This study revealed that 6 factors were independently associated with hematoma expansion. Male patient was an independent predictor. Hematoma expansion occurred more often in male patients. Our study included a Chinese population, and only a few of the women had smoking and drinking habits because of the Chinese tradition. Smoking and drinking were potential risk factors of hematoma expansion \[[@bb0060],[@bb0155]\]. The sex difference of hematoma expansion may be caused by the difference of living habits between men and women. The time interval from onset to baseline CT was confirmed as a significant predictor of hematoma expansion in our study. Previous research reported that the incidence of hematoma expansion decreased as the time interval from onset to baseline CT increased. Patients admitted earlier after symptom onset might have a relatively high possibility of undergoing a CT scan before the stabilization of hematoma growth \[[@bb0060]\]. Glasgow Coma Score provides a reliable and objective way of recording the conscious state of a patient for initial as well as subsequent assessment. Patients with disturbed consciousness had a likelihood of having hematoma expansion \[[@bb0060]\]. Our study demonstrated that expanders had lower Glasgow Coma Score than nonexpanders. Fibrinogen plays a significant role in platelet aggregation and glycoprotein IIa/IIIb on the surface of platelets requires fibrinogen for aggregation, and low levels of fibrinogen might be associated with an impairment of hemostasis \[[@bb0060]\]. Black hole sign and blend sign have been proved to be significantly correlated with hematoma expansion recently \[[@bb0025],[@bb0105]\]. Our study further confirmed these findings. Both black hole sign and blend density sign imply the heterogeneity of hematoma. The presence of the two signs within hematoma may reflect different age of bleeding; fresh blood shows hypoattenuating on nonenhanced CT scan; after clot retraction, serum sequesters out of hematoma, which make the bleed hyperintense on CT scan \[[@bb0160]\].

Various variables have been used to predict hematoma expansion. Quantitative CT densitometry values of ICH density distribution were adopted for predicting intracerebral hemorrhage growth, and AUC of 0.73 was obtained with a conventional binary logistic regression model incorporating baseline hematoma volume, time-to-scan, and coefficient of variation of ICH attenuation \[[@bb0165]\]. A novel imaging sign, black hole, was found to be independent predictor, based on which a sensitivity of 32% was achieved in predicting early hematoma growth \[[@bb0025]\]. More recently, island sign was proposed for predicting early hematoma expansion and poor outcome in patients with ICH; corresponding prediction sensitivity of the island sign was 45% \[[@bb0140]\]. The spot sign of computed tomography angiography (CTA) was well-established imaging marker of hematoma expansion; a recent prospective observational study \[[@bb0170]\] reported that sensitivity of the spot sign in predicting hematoma expansion was 51%. In addition to CTA spot sign, leakage sign on delayed-phase CT after CTA was valuable to predict hematoma expansion, and corresponding sensitivity was even as high as 93% \[[@bb0175]\]. However, delayed-phase CT after CTA is not a routine examination; an additional CT scan was required to confirm the leakage sign and patient would suffer greater radiation exposure \[[@bb0175]\]. Moreover, contrast administration may be not applicable for patients with kidney disease or severe diabetes because X-ray contrast medium can further harm kidney function \[[@bb0025],[@bb0180]\]. Machine learning is capable of effectively learning from training data to make accurate predictions or decisions on new data, and has been successfully applied for hemorrhage detection in CT scans \[[@bb0185]\], outcome prediction of patients with subarachnoid hemorrhage \[[@bb0190]\], and mortality prediction of spontaneous ICH \[[@bb0195]\]. The novelty of our work was the use of SVM machine learning technique to predict hematoma expansion from routinely available variables. Our model achieved an average sensitivity of 81.3%, a specificity of 84.8%, and an AUC of 0.89, which indicated that our model presented good performance in prediction of hematoma expansion and might be widely applied in clinics.

There are several limitations in our study. First, our study data were collected from two affiliated hospital of our university in the same city; the population may not represent the general ICH populations. Second, as a retrospectively study, timing of the follow-up CT scan was not standardized, which may limit our model in other institutions. Third, as a machine learning technique, SVM required hardware and software configuration, and each institution would need the technical knowledge to perform the analysis. Finally, our model require different features of patients\' demographic factor, neurological status, parameter from laboratory test, time to initial CT scan, CT imaging characteristics. To use the model, same features of a patient should be provided; however, these features may not be readily available in all hospitals.

In summary, we conducted multivariate analysis of predictors of hematoma expansion in spontaneous ICH and predicted hematoma expansion by using SVM approach. The SVM model demonstrated good performance in predicting hematoma expansion. Moreover, the developed SVM model was based on simple routinely available variables and corresponding clinical examinations to acquire these variables were safe to patients. Those who are predicted to suffer hematoma expansion using SVM model may benefit from the intervention. Therefore, our prediction model may be practical and widely applicable, especially in many institutions where CTA is not readily available or routinely performed for spontaneous ICH patients.

Funding sources {#s0065}
===============

This work was supported by Health Foundation for Creative Talents in Zhejiang Province, China, Natural Science Foundation of Zhejiang Province, China (LQ15H180002), the Science and Technology Planning Projects of Wenzhou, China (Y20180112), Scientific Research Staring Foundation for the Returned Overseas Chinese Scholars of Ministry of Education of China, and Project Foundation for the College Young and Middle-aged Academic Leader of Zhejiang Province, China. The funders had no role in study design, data collection, data analysis, interpretation, writing of the report.

Declaration of interests {#s0070}
========================

The authors declare no conflict of interests.

Author contributions {#s0075}
====================

Y.J.Y. and W.J.C. were the principal investigator; Y.J.Y., W.J.C., and J.J.L. designed the research. J.J.L. drafted the manuscript. H.L.X., Q.C., T.T.Z., W.S.S., Q.H., J.W.S., D.P.H., L.L., and Y.X.L. collected data. J.J.L. analyzed the data. All authors reviewed and approved the manuscript.

[^1]: Note: HDL-C = high density lipoprotein cholesterol, LDL-C = low density lipoprotein cholesterol.

[^2]: 30/1157 (2.6%) missing values.

[^3]: 4/1157 (\<1.0%) missing values.

[^4]: 7/1157 (\<1.0%) missing values.

[^5]: 146/1157 (12.6%) missing values.

[^6]: 88/1157 (7.6%) missing values.

[^7]: 112/1157 (9.7%) missing values.

[^8]: 185/1157 (16.0%) missing values.

[^9]: 28/1157 (2.4%) missing values.

[^10]: Note: OR = odds ratio, CI = confidence interval.

[^11]: Values are means ± standard errors.
